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ABSTRACT
Objective: Monolithic matrix tablets of metformin hydrochloride were formulated as extended-release tablets by employing ethyl cellulose (EC) 
polymer and the extended release characterization of the formulated tablets was investigated.
Methods: Extended release matrix tablets containing 500 mg metformin hydrochloride were developed by changing concentration of drug: Polymer 
(EC) in the ratio of 5:1, 5:2, 5:3, and 5:4 by direct compression. Formulations were optimized based on the acceptable tablet properties in vitro and 
in vivo drug release.
Results: The resulting formulations produced robust tablets with optimum hardness, weight variation, drug content, and low friability. The result of 
in vitro and in vivo drug release studies indicated that formulation (drug:polymer=5:3) is the most successful of the study and exhibited constant and 
extended release of metformin hydrochloride release at the end of 10 hrs compared with a reference standard. A decrease in release of the drug was 
observed on increasing polymer ratio at a certain level. Further, the formulation F3 was subjected to exposure at room and accelerated condition to 
stability studies. There is no difference between storage temperatures.
Conclusion: The formulation F3 was concluded that the similar in vitro and in vivo drug release pattern was observed when compared to marketed 
sustained release tablet (F5M).
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NTRODUCTION
Metformin hydrochloride is an orally administered biquanide, which is 
widely used in the management of Type 2 diabetes, a common disease 
that combines defects of both insulin secretion and insulin action [1]. 
It improves hepatic and peripheral tissue sensitivity to insulin without 
the problem of serious lactic acidosis commonly found with us analog, 
phenformin. It has 3 different actions: (1) It shows the absorption at sugar 
in our small intestine, (2) it also stops our liver from converting stored 
sugar into blood sugar, and (3) it helps our body use our natural insulin 
more efficiently. It is hydrophilic drug and is slowly and incompletely 
absorbed from the gastrointestinal (GIT) tract and the absolute 
bioavailability of a single 500 mg dose is reported to be 50-60% [2]. 
An obstacle to more successful use of metformin therapy is the high 
incidence of concomitant GIT symptoms such as abdominal discomfort, 
nausea, and diarrhea. Those especially occur during the initial weeks of 
treatment. The compound has also relatively short plasma elimination 
half-life of 1-4 hrs [3,4]. Side effect and the need for administration two 
or three times per day when larger doses are required can decrease 
patient compliance. Extended release formulation that would maintain 
plasma levels of drug for 8-12 hrs might be sufficient for once daily 
dosing for metformin. Extended-release (sustained release) products 
are needed for metformin to prolong us the duration of action and to 
improve patient compliance [2,5].
Several authors have reported the use of ethyl cellulose (EC) 
matrices to control the release of variety of drugs such as 
zidovudine, cimetidine, potassium chloride, isosorbide dinitrate, and 
theophylline, etc., for a variety of reasons. Therefore, in this study, 
the different concentrations of hydrophobic polymer (EC) have 




Metformin hydrochloride - USP was gift sample from wockhardt 
pharmaceuticals (Mumbai, India), EC (18 cP) was procured from so fine 
Chemicals Ltd. (Mumbai, India). Micro crystalline cellulose powder I.P. 
was obtained from Sigha Enichlro Chemicals Pvt. Ltd., (India). Sodium 
Chloride injection IP. Mount Mettur Pharmaceutical Ltd., (Tamil Nadu, 
India). Alloxan, Loba Chemie (Bombay, India). All other chemicals and 
reagents used were of the high analytical grade. Double distilled water 
was used for evaluation studies.
Machineries
Machineries and equipment used were tablet compression machine, 
(Cadmach Machinery Co. Pvt. Ltd.). Ultraviolet (UV)-visible 
spectrophotometer, (Shimadzu 1700); six stage dissolution rate test 
apparatus IP/BP/USP, (tab machines). Friability test apparatus (Remi 
equipment Pvt. Ltd.). Monsanto hardness test apparatus, (Rollex Pvt. 
Ltd.) India, B. S. Sieves, (Jaynant scientific) and tray dryer (Mumbai 
engineering works). Differential scanning colorimeter (perkin elemer 
differential scanning calorimetry [DSC]-7 model) blood glucose 
monitoring system (smartcare TD-4227), saify traders (Indore, India). 
Stability chamber (environmental chamber). The Ileco, (Chennai, 
India).
Animals
Swistar albino rats (200-250 g) from Central Animal House, 
Adhiparasakthi College of Pharmacy, (Melmaruvathur, Tamil Nadu, 
India) were used in this study. The protocol for the animal experiment 
was approved by Institutional Animal Ethics Committee which follows 
the norms of CPCSEA (India).
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Methods
Preparation of metformin hydrochloride extended release matrix 
tablets
Different tablet reformulations F1 to F4 were prepared by direct 
compression technique [15]. Ingredients required for per tablet are 
given in Table 1 and tabulated as follows. The metformin hydrochloride, 
EC (18 cps) and microcrystalline cellulose (Avicel) powders were 
separately passed through mesh No: 44. Powders were uniformly 
blended in a double cone blender for 5 minutes. Then, the dried 
powders were lubricated with magnesium stearate and aerosil by 
mixing in a rapid mixer at slow speed for 5 minutes. Separately each 
formulation was compressed using 16/32 inch flat punches in Cadmach 
tablet compression machine to get tablets.
Evaluation of powder blends
The formulated powder blends were evaluated for compatibility, angle 
of repose, bulk density, true density, percentage compressibility index, 
and total percentage porosity.
Evaluation of tablets
The compressed tablets formulations (F1 to F4) and reference standard 
(F5M) (marketed sustained release tablet) were evaluated for hardness, 
percentage friability, percentage weight variations, and the percentage 
drug content.
In vitro release studies
The in vitro dissolution studies were carried out [20,21] all formulated 
tablet (F1 to F4) out using six stage dissolution test apparatus IP/BP/USP 
at 50 rpm. The dissolution medium consisted of simulated gastric fluid 
(pH 1.2-acid buffer) (for first 2 hrs) and followed in simulated intestinal 
fluid (pH 7.2-phosphate buffer) from 2 to 10 hrs (900 ml), maintained 
at 37°C±±0.5°C. Samples were taken at predetermined time intervals 
and analyzed for metformin hydrochloride content at 227.5 nm and 
230 nm in UV-visible spectrometer, respectively, and compared with 
the blank. The same procedure was followed reference standard (F5M).
In vivo release studies
Diabetes was induced in healthy Wistar albino rats of either sex 
weighing (200-250 g) by injecting a single intraperitoneal injection of 
150 mg/kg body weight of alloxan monohydrate. Blood glucose level was 
checked after 48 hrs. Animal with blood glucose level >250 mg/dl were 
considered diabetic and were selected for our further study [25-27].
The rats were divided into 4 groups of rats each group having 6 rats and 
Group I animal served as normal control, they were not given any drug. 
The Groups II, III, and IV were diabetic rats. From the Groups (II-IV), 
Group II animal are diabetic control rats. The Groups III and IV were 
given formulated metformin hydrochloride matrix tablet formulation 
F3 and reference standard (F5M), respectively, in the form of suspension 
orally at a dose level of 450 mg/kg body weight. On fasting, blood 
samples were collected from the tail vein on the 3rd day of each Groups 
(I-IV) at 0, 1, 2, 4, 6, 8, 10 hrs, intervals. Glucose levels were estimated 
using glucosemeter. Statistical comparisons with animal of non-treated 
groups of control I and II with drug-treated groups were performed with 
Student’s t-test. Data were expressed as mean±standard error mean.
RESULTS AND DISCUSSION
Metformin hydrochloride is a highly water-soluble drug. Its poor 
inherent compressibility coupled with high dose (500 mg) a significant 
challenge for developing an extended release dosage form. For 
developing extended release matrix tablet with desirable drug release 
profile, cost effectiveness and broader regulatory acceptance, different 
concentration EC (18 cP) was chosen as a release controlling polymer.
Compatibility study of metformin hydrochloride by DSC
DSC thermogram of pure metformin hydrochloride and blend of 
polymer mixture with drug were determined (Fig. 1) [11-13]. 
Different in the peak area in the thermograms of blend of drug in 
the polymer from that of pure drug is due to less quantum of drug in 
the blend. Absence of any new endothermic peak is disappearance 
of no shift of endothermic peak confirm that peak in thermogram of 
pure drug and the blend of drug in the polymer confirms that there 
is no any interaction, and hence the polymer are compatable with 
the drug.
Evaluation of physico-chemical parameters of formulated powder 
blends
Formulation of proper powder blend is the key factor in the 
production of tablet dosage form involving extended release of a 
drug from matrix type particle. Physical parameters such as specific 
surface area, shape, hardness, surface characteristics and size 
can significantly affect the rate of dissolution of drugs contained 
in a complex system. The formulated powder blends of different 
formulations (F1 to F4) were evaluated for angle of repose, true 
density, bulk density, compressibility index, and total percentage 
porosity [14-17] (Table 2). The results of angle of repose (<30) 
indicated good flow properties of all the formulated powder blends 
except one (F4). The compressibility index value recorded <15%, 
results in good to excellent flow properties in two formulations (F2 
and F3) supporting the angle of repose indicating good flow, which in 
rest of the formulation it can >15%.
The formulated powder blend density, porosity and hardness are often 
interrelated properties and are likely to influence compressibility, 
porosity, dissolution profile and other properties of tablets made 
from it, the percentage porosity value ranged from 8.89% to 29.13% 
indicating that the packing of the powder blend may range from close 
to loose packing and also confirm that the particle is not of greatly 
different sizes. In general, a percentage porosity value below 26% 
shows that the particle in the powders are of greatly different sizes, 
and a values >4.8% percentage shows that particle in the powder are 
in the form aggregates or flocculates. All these results indicate that the 
formulated powder blends processed satisfactory flow properties and 
compressibility.
Evaluation of formulated tablets
The tablet of different formulations (F1 to F4) and reference standard 
(F5M) was evaluated for various parameters, viz., hardness, friability, % 
weight variation, and % drug content. The results of these parameters 
are given in Table 3. The results are compared with the reference 
standard (F5M) and also confirm with the official and OPPI standards 
for tablets [18-21].
Table 1: Composition of tablet formulations F1 to F4
Ingredients (per tablet) (mg) Formulations
F1 F2 F3 F4
Metformin hydrochloride 500 500 500 500
Ethyl cellulose (18 centipoise) 100 200 300 400
Microcrystalline cellulose 75 75 75 75
Colloidal silicone dioxide (aerosil) 0.006 0.006 0.006 0.006
Magnesium stearate 0.012 0.012 0.012 0.012
Table 2: Physical and chemical parameters of formulated 
metformin hydrochloride powder blends with 
polymers (F1to F4)
Evaluation parameters Formulations
F1 F2 F3 F4
Angle of repose (degree) 23.35 23.19 23.75 30.02
Bulk density (g/ml) 0.69 0.58 0.56 0.65
Compressibility index (%) 16.05 12.72 12.72 16.67
Porosity (%) 29.13 11.40 11.40 18.89
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In vitro release studies
Results of the in vitro release studies and manufactured along with 
reference standard formulation (a marketed sustained release product) 
are presented in Tables 4-6 are shown in Fig. 2.
The plot of cumulative percentage in vitro drug release profile of 
metformin hydrochloride from four formulations F1, F2, F3, and F4 made 
with different concentration of EC (18 cP) in simulated gastric fluid 
(pH 1.2-acid buffer) (for first 2 hrs) followed by simulated intestinal 
fluid (pH 7.2-phosphate buffer) [20,21] for 10 h is shown in Fig. 3. It is 
found that the cumulative percentage drug release of the formulation F1 
is faster than formulations F2, F3, and F4, with formulation F4 showing the 
slowest release and unsatisfactory. Release profile of F3 is comparable 
to reference standard (F5M). Hence, it can be inferred that a proportion 
of EC (18 centipoise) is increased to release is retarded and drug: EC 
ratio of 5:3 is found to be optimum for comparable release profile of 
reference standard (F5M).
Stability studies on in vitro release
The selected formulation F3 was subjected up to 6 months stability 
study as per International Congress on Harmonization (ICH) guidelines 
at room temperature (25°C±2°C and 60%±5% relative humidity [RH]) 
and accelerated condition (40°C±2°C and 75%±5% RH) to find out the 
effect of aging on release pattern [24]. The results of the stability study 
do not indicate any significant alteration in the in vitro release pattern 
of the drug from the tablet. The results are furnished Tables 7-10 and 
presented graphically in Fig. 4.
Cumulative percentage release versus time plot drug release data 
from selected formulation F3, after 6 months of exposure to stability 
testing condition at room temperature and accelerated condition as 
per ICH guidelines in simulated gastric fluid (pH1.2-acid buffer) (for 
first 2 hrs) followed by stimulated intestinal fluid (pH 7.2-phosphate 
buffer). The data are shown in Tables 5 and 6 depicted in Fig. 4. There 
is no significant difference in the in vitro release formulation F3 and 
compared with a reference standard (F5M) before and after stability 
studies.
Table 4: Comparative in vitro release profiles on metformin hydrochloride matrix tablet formulations (F1 to F4) and reference 
standard (F5M)*
Time (minutes) pH F1 F2 F3 F4 F5M
























































































*All values are mean±SD and % RSD for n=3
Fig. 1: Compatibility analysis of metformin hydrochloride and polymer(s) by differential scanning calorimetry. (a) Metformin 
hydrochloride. (b) Metformin hydrochloride and ethyl cellulose
a b
Table 3: Physical and chemical parameters of formulated 
metformin hydrochloride compressed tablet formulations 
(F1 to F4) and marketed formulation (FM)*
Evaluation parameters Formulations
F1 F2 F3 F4 FM
Hardness (kg/cm2) 8.00 8.33 8.67 8.00 8.00
Friability (%) 0.78 0.59 0.55 0.33 0.39
Weight variation (%) 0.63 0.86 0.56 1.10 0.51
Drug content (%) 99.40 99.20 100.20 99.20 100.4
*All values are mean±SD and % RSD for n=3
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Table 5: Regression coefficient values (R2) of selected sustained release matrix tablets of metformin hydrochloride 
(formulations F3 and FM)







Table 6: Stability studies of in vitro release profiles on tablet formulation F3 at room temperature (25°C±2°C at 60%±5% RH) in the 
period of 6-month*
Time (minutes) pH 1st Month 2nd Month 3rd Month 4th Month 5th Month 6th Month
























































































































*All values are mean±SD and % RSD for n=3
Comprehensive data of in vitro release rate studies were showing t25 
(time of 25% drug release), t50 (time of 50% drug release), and t90 (time 
of 90% drug release) values were determined of formulation F3 at room 
and accelerated condition was shown in Fig. 3 (Tables 5 and 6). All the 
data of t25, t50, and t90 in vitro release rate study values are applying 
paired t-test was shown in Table 10. There is no significant difference 
between room and accelerated condition at p<0.001 for formulation F3. 
Hence, the formulation F3 was selected best formulation.
In vivo release studies
From the t-test, comparison of F3 and reference standard (F5M), 
t calculated value <t table value (0.001<2.34), therefore accepted the 
null hypothesis. There is no difference between F3 and F5M. Hence, the 
formulation F3 was similar as the reference standard (F5M) to produced 
extended release to lower the blood glucose level in animal at tested 
dose level (Tables 11 and 12) [25-27]. The pharmacokinetic studies 
results were shown in Table 13 and Fig. 5.
Fig 2: Plot of in vitro release profile in simulated gastric fluid (pH 1.2-acid buffer) (for first 2 hrs) followed by simulated intestinal fluid 
(pH 7.2-phosphate buffer) for ethyl cellulose based metformin hydrochloride matrix tablet formulations
Asian J Pharm Clin Res, Vol 9, Issue 6, 2016, 309-315
 Moorthy and Kumar 
313
Table 7: Stability studies of in vitro release profiles on tablet formulation F3 at accelerated temperature (40°C±2°C at 75%±5% RH) in 
the period of 6-month*
Time (minutes) pH 1st Month 2nd Month 3rd Month 4th Month 5th Month 6th Month
























































































































*All values are mean ± SD and % RSD for n = 3
Fig. 3: Plot of stability studies on in vitro release profile at room temperature (25°C±2°C and 60 %±5% RH) and accelerated temperature 
(40°C±2°C and 75±5% RH) in simulated gastric fluid (pH 1.2-acid buffer) (for first 2 hrs) tablet formulations F3 for 6 months
Fig. 4: Histogram of stability studies on in vitro release profile at room temperature (25°C±2°C and 60%±5% RH) and accelerated 
temperature (40°C±2°C and 75%±5% RH) of t25 t50 and t90 values for ethyl cellulose based metformin hydrochloride matrix tablet 
formulations F3 for 6 months
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CONCLUSION
Based on in vitro t25, t50 and t90 and in vivo drug release, formulation F3 was 
found to have a selective drug release pattern among the formulations 
prepared. The values were compared with a reference standard 
(F5M) and were subjected to stability study at room and accelerated 
temperature to find out the effect of aging on release pattern. The result 
of this stability study does not indicate any significant alteration in the 
in vitro release pattern of the drug from the matrix tablet. Formulation 
F3 found to be stable on storage and does not exhibit any alteration in 
its release pattern. Hence, it was concluded that formulation, F3 was 
selected as best formulation.
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Table 8: Stability studies on in vitro release profile of t25, t50, and t90 on formulation F3 at room temperature and accelerated temperature 
in the period of 6 months*
Period in 
month
Room temperature (25°C±2°C at 60%±5% RH) Accelerated temperature (40°C±2°C at 75%±5% RH)
t25 (hrs) t50 (hrs) t90 (hrs) t25 (hrs) t50 (hrs) t90 (hrs)
1st month 1.05 2.37 8.10 1.02 3.39 8.00
2nd month 1.06 2.32 8.05 1.04 2.30 8.30
3rd month 1.10 2.34 8.20 1.06 2.31 8.00
4th month 1.12 2.64 8.32 1.05 2.60 8.55
5th month 1.06 2.36 8.00 1.32 3.41 8.40
6th month 1.11 2.37 8.30 1.05 2.45 9.30
*All values are mean for n=3
Table 9: Regression coefficient values (R2) of selected sustained release matrix tablets of Metformin hydrochloride (formulations F3 and 
FM) after 12 month of stability studies at 25°C±2°C at 60%±5% RH
Formulations 0 order 1st order Higuchi model Korsmeyer and Peppas model
F3 0.9831 0.9911 0.9781 0.9669
FM 0.9675 0.9528 0.9950 0.9912
RH: Relative humidity
Table 10: Regression coefficient values (R2) of selected sustained release matrix tablets of metformin hydrochloride (formulations F3 
and FM) after 6 months of stability studies at 40°C±2°C at 75%±5% RH
Formulations 0 order 1st order Higuchi model Korsmeyer and Peppas model
F3 0.8976 0.9833 0.9815 0.9676
FM 0.9576 0.9921 0.9896 0.9860
RH: Relative humidity




Blood sugar in mg/dl (hrs)±SEM
0 1 2 4 6 8 10
I Normal (control) 99.67±2.26 100.12±2.02 97.13±1.89 102.44±2.10 110.39±2.31 95.91±1.76 103.33±1.74
II Diabetic control 
(Streptozocin)
502.17±1.38 509.06±1.42 517.77±1.33 522.88±1.02 531.12±1.18 536.46±1.21 544.17±0.99
III Formulation 
F3 (450)
483.83±3.91 474.33±4.10 458.00±4.62 433.83±5.25 397.67±4.78 321.50±3.31 309.00±3.66
IV Reference standard 
F5M (450)
499.83±1.66 492.17±2.01 469.17±2.55 436.50±3.91 390.33±3.91 333.00±3.76 339.67±3.95
*All values are mean±standard mean error for n=6
Table 12: t-test inferential studies for determination of blood glucose level by animal studies for formulation F3 with reference standard (F5M)
Formulations Mean Standard deviation Degree of freedom t calculated value t table value p value
F3 423.09 53.30 10 0.003 2.34 p>0.01
F5M 422.80 69.75 - - -
Table 13: Mean plasma drug concentration of metformin 
hydrochloride matrix tablet formulation of reference 
standard, FM, F3




0 0 0 0
0.5 1.26±0.09 1.24±0.14 1.10±0.10
1 1.47±0.08 1.31±0.13 1.22±0.09
2 2.15±0.15 1.69±0.04 1.60±0.02
4 0.91±0.11 0.95±0.06 0.91±0.11
6 0.05±0.01 0.70±0.06 0.60±0.09
8 0.05±0.02 0.34±0.07 0.32±0.09
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Fig. 5: Plasma drug concentration versus time curve of metformin 
hydrochloride matrix tablet formulations of F3, FM reference 
standard in rabbit
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